Cardiff Oncology Corp (CRDF): Price-to-Revenue Ratio

Brandmark of cardiffoncology.com (CRDF)

Cardiff Oncology, Inc. (CRDF) focuses on developing targeted therapies based on a rigorous scientific approach and clinician expertise. The historical P/S trend on this GURU.Markets chart, where 101.30 captures the current indicator value, highlights the pressure from pharma behemoths in the battle for patents. High R&D expenditures define the financial profile, keeping margins at a preparatory level.

CRDF Cardiff Oncology P/S Multiple (07/04/2022 - 11/15/2026)

Cardiff Oncology Inc. (CRDF) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price Cardiff Oncology Inc.|CRDF - Price Target Chart
- stock exchange capitalization data:
Market Value Cardiff Oncology|CRDF - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Cardiff Oncology|CRDF - Book Capitalization|Market Value to Equity Ratio cardiffoncology.com|CRDF - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Cardiff Oncology, Inc.|CRDF - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Cardiff Oncology Corp|CRDF - Company Total Debt|Debt to Book Capital Cardiff Oncology, Inc.|CRDF - Company Long-Term Debts|Company Short-Term Loans and Borrowings Cardiff Oncology|Immediate Liquidity cardiffoncology.com
- earnings and multiples data:
CRDF - Company Net Income|Expected Net Income Cardiff Oncology, Inc.|CRDF - P/E Multiple|Forward P/E Multiple Cardiff Oncology Inc.|CRDF - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Cardiff Oncology, Inc.|CRDF - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Cardiff Oncology|CRDF - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months cardiffoncology.com|CRDF - Earnings growth in current year|Earnings growth forecast for next year Cardiff Oncology, Inc.
- issuer revenue and sales details:
CRDF - Company Revenue|Company Future Revenue Cardiff Oncology|CRDF - P/S Multiple|Market Cap to Projected Revenue Cardiff Oncology, Inc.|CRDF - Sales Growth YoY (TTM)
Summary company analytics:Cardiff Oncology Corp
Mass-produced product of Cardiff Oncology

The P/S ratio determines the market value of a single ruble of revenue, allowing investors to distinguish between objective capitalization and speculative market expectations. By analyzing the price-to-sales multiple, one can assess the valuation volatility of Cardiff Oncology, Inc. (CRDF), where a high price-to-sales ratio reflects confidence in the success of innovative PLK1 inhibitors amid fierce biotech competition and dependence on clinical trial results.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio hutch-med.com HCM|Nuvation Corp - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Therapeutics|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics, Inc. HRTX|Market Cap to Revenue NVCT (Nuvectis Pharma, Inc.)|CHRS (Coherus BioSciences) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume BYSI (BeyondSpring)|BioAtla - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings)|CTXR: P/S Multiple|Price to Sales cellectar.com (CLRB)|Price-to-Revenue Ratio BioLineRx|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple Kazia Therapeutics Ltd (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales Cyclacel|GTHX: P/S Multiple|Kronos Bio Corporation (KRON) - P/S Multiple|KTRA (kintara.com) - P/S Multiple|Market Cap to Revenue Ratio ONCT (Oncternal Therapeutics)|Price-to-Revenue Ratio Portage Biotech (PRTG)